Genomtec S.A. (GMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genomtec S.A. (GMT) has a cash flow conversion efficiency ratio of -0.262x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.84 Million ≈ $-506.39K USD) by net assets (zł7.02 Million ≈ $1.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Genomtec S.A. (GMT) market capitalisation for the company's overall valuation and market capitalisation.
Genomtec S.A. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genomtec S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genomtec S.A. ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Genomtec S.A. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volt Power Group Ltd
AU:VPR
|
0.043x |
|
Blue Energy Ltd
AU:BLU
|
-0.009x |
|
OXE Marine AB
ST:OXE
|
-0.326x |
|
Enerside Energy S.A.
MC:ENRS
|
-2.096x |
|
Sab Events & Governance Now Media Limited
NSE:SABEVENTS
|
-0.005x |
|
ZincX Resources Corp
V:ZNX
|
-0.004x |
|
Lode Resources Ltd
AU:LDR
|
-0.055x |
|
Société Hôtelière et Immobilière de Nice S.A.
PA:MLHIN
|
N/A |
Annual Cash Flow Conversion Efficiency for Genomtec S.A. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Genomtec S.A. from 2019 to 2024. View GMT live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł7.60 Million ≈ $2.09 Million |
zł-6.72 Million ≈ $-1.85 Million |
-0.884x | +7.74% |
| 2023-12-31 | zł8.30 Million ≈ $2.28 Million |
zł-7.95 Million ≈ $-2.19 Million |
-0.958x | -24.64% |
| 2022-12-31 | zł4.93 Million ≈ $1.36 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.768x | +89.74% |
| 2021-12-31 | zł738.00K ≈ $203.11K |
zł-5.53 Million ≈ $-1.52 Million |
-7.491x | -2155.20% |
| 2020-12-31 | zł7.57 Million ≈ $2.08 Million |
zł-2.52 Million ≈ $-692.16K |
-0.332x | +78.32% |
| 2019-12-31 | zł1.11 Million ≈ $304.34K |
zł-1.69 Million ≈ $-466.31K |
-1.532x | -- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more